JP2023509880A - 加齢黄斑変性の治療における融合タンパク質の使用 - Google Patents

加齢黄斑変性の治療における融合タンパク質の使用 Download PDF

Info

Publication number
JP2023509880A
JP2023509880A JP2022538928A JP2022538928A JP2023509880A JP 2023509880 A JP2023509880 A JP 2023509880A JP 2022538928 A JP2022538928 A JP 2022538928A JP 2022538928 A JP2022538928 A JP 2022538928A JP 2023509880 A JP2023509880 A JP 2023509880A
Authority
JP
Japan
Prior art keywords
eye
letters
characters
weeks
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509880A5 (https=
JPWO2021129658A5 (https=
Inventor
シューチエ ルー
レイ チエン
Original Assignee
イノベント バイオロジクス（スーチョウ）カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベント バイオロジクス（スーチョウ）カンパニー，リミティド filed Critical イノベント バイオロジクス（スーチョウ）カンパニー，リミティド
Publication of JP2023509880A publication Critical patent/JP2023509880A/ja
Publication of JP2023509880A5 publication Critical patent/JP2023509880A5/ja
Publication of JPWO2021129658A5 publication Critical patent/JPWO2021129658A5/ja
Priority to JP2024127939A priority Critical patent/JP2024167222A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022538928A 2019-12-24 2020-12-23 加齢黄斑変性の治療における融合タンパク質の使用 Pending JP2023509880A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024127939A JP2024167222A (ja) 2019-12-24 2024-08-02 加齢黄斑変性の治療における融合タンパク質の使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911346311.2 2019-12-24
CN201911346311 2019-12-24
CN202011441025 2020-12-11
CN202011441025.7 2020-12-11
PCT/CN2020/138598 WO2021129658A1 (zh) 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024127939A Division JP2024167222A (ja) 2019-12-24 2024-08-02 加齢黄斑変性の治療における融合タンパク質の使用

Publications (3)

Publication Number Publication Date
JP2023509880A true JP2023509880A (ja) 2023-03-10
JP2023509880A5 JP2023509880A5 (https=) 2023-06-05
JPWO2021129658A5 JPWO2021129658A5 (https=) 2023-06-05

Family

ID=76575187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538928A Pending JP2023509880A (ja) 2019-12-24 2020-12-23 加齢黄斑変性の治療における融合タンパク質の使用
JP2024127939A Pending JP2024167222A (ja) 2019-12-24 2024-08-02 加齢黄斑変性の治療における融合タンパク質の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024127939A Pending JP2024167222A (ja) 2019-12-24 2024-08-02 加齢黄斑変性の治療における融合タンパク質の使用

Country Status (8)

Country Link
US (1) US20230056821A1 (https=)
EP (1) EP4082559A4 (https=)
JP (2) JP2023509880A (https=)
CN (2) CN118750581A (https=)
AU (2) AU2020414152B2 (https=)
CA (1) CA3165887A1 (https=)
TW (2) TWI879855B (https=)
WO (1) WO2021129658A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500811A (ja) * 2011-12-01 2015-01-08 プロテボビオ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
JP2017535557A (ja) * 2014-09-25 2017-11-30 イノベント バイオロジックス インコーポレーテッドＩｎｎｏｖｅｎｔ Ｂｉｏｌｏｇｉｃｓ，Ｉｎｃ 組み換え融合タンパク質製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104940926B (zh) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500811A (ja) * 2011-12-01 2015-01-08 プロテボビオ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
JP2017535557A (ja) * 2014-09-25 2017-11-30 イノベント バイオロジックス インコーポレーテッドＩｎｎｏｖｅｎｔ Ｂｉｏｌｏｇｉｃｓ，Ｉｎｃ 組み換え融合タンパク質製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EXPERIMENTAL EYE RESEARCH, vol. 145, JPN6023027856, 2016, pages 352 - 358, ISSN: 0005105647 *

Also Published As

Publication number Publication date
EP4082559A4 (en) 2024-01-03
CN114867489A (zh) 2022-08-05
AU2025203373A1 (en) 2025-05-29
EP4082559A1 (en) 2022-11-02
AU2020414152A1 (en) 2022-08-04
CN118750581A (zh) 2024-10-11
AU2020414152B2 (en) 2025-02-13
US20230056821A1 (en) 2023-02-23
TWI879855B (zh) 2025-04-11
CA3165887A1 (en) 2021-07-01
JP2024167222A (ja) 2024-12-03
WO2021129658A1 (zh) 2021-07-01
TW202525865A (zh) 2025-07-01
TW202128746A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
US12280093B2 (en) Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy
JP2025169389A (ja) 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2024167222A (ja) 加齢黄斑変性の治療における融合タンパク質の使用
Gamble et al. Experimental uveitis: I. The production of recurrent immunologic (Auer) uveitis and its relationship to increased uveal vascular permeability
JP7828274B2 (ja) 眼疾患を治療するための方法
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
WO2025036488A9 (en) Methods of treating age-related macular degeneration and diabetic macular edema
KR20260054713A (ko) 노인성 황반 변성 및 당뇨병성 황반 부종의 치료 방법
Hakan et al. Evaluation Of The Effectiveness Of Intravitreal Anti-VEGF Injection With Intravitreal Dexamethasone Implant In Patients With Treatment-Resistant Diabetic Macular Edema
HK40094966A (en) Use of a vegf antagonist to treat diabetic retinopathy
HK40125761A (en) Use of a vegf antagonist to treat angiogenic eye disorders
EA046420B1 (ru) Применение антагониста vegf для лечения ангиогенных глазных заболеваний
JP2026072102A (ja) 眼疾患を治療するための方法
EA051980B1 (ru) Расширенные схемы применения высоких доз антагониста vegf для лечения ангиогенных нарушений со стороны глаза
HK40038974A (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK40038974B (en) Use of a vegf antagonist to treat angiogenic eye disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240913